Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Short term Debt (2016 - 2019)

Historic Short term Debt for Outlook Therapeutics (OTLK) over the last 5 years, with Q3 2019 value amounting to $6.7 million.

  • Outlook Therapeutics' Short term Debt rose 997671.48% to $6.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $6.7 million, marking a year-over-year increase of 997671.48%. This contributed to the annual value of $6.7 million for FY2019, which is 997671.48% up from last year.
  • According to the latest figures from Q3 2019, Outlook Therapeutics' Short term Debt is $6.7 million, which was up 997671.48% from $6.7 million recorded in Q2 2019.
  • Outlook Therapeutics' Short term Debt's 5-year high stood at $12.8 million during Q2 2018, with a 5-year trough of $52600.0 in Q3 2017.
  • Its 5-year average for Short term Debt is $5.9 million, with a median of $6.7 million in 2017.
  • Per our database at Business Quant, Outlook Therapeutics' Short term Debt tumbled by 9103.08% in 2017 and then soared by 997671.48% in 2019.
  • Outlook Therapeutics' Short term Debt (Quarter) stood at $742646.0 in 2015, then surged by 564.34% to $4.9 million in 2016, then soared by 147.11% to $12.2 million in 2017, then fell by 25.7% to $9.1 million in 2018, then dropped by 26.04% to $6.7 million in 2019.
  • Its Short term Debt stands at $6.7 million for Q3 2019, versus $6.7 million for Q2 2019 and $7.6 million for Q1 2019.